Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2022 | Early results on the safety and efficacy of allogeneic TruUCAR™ GC502 in patients with R/R B-ALL

Xinxin Wang • 14 Apr 2022
AACR 2022
Acute Lymphoblastic Leukemia Leukemia CAR-T TruUCAR™ GC502

In this video, Xinxin Wang, PhD, Gracell Biotechnologies, San Diego, CA, shares some early results from a study investigating the safety and efficacy of allogeneic TruUCAR™ GC502 for patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). Dr Wang highlights the promising results of this study, including the response rates observed in patients, as well as the adverse events (AEs). This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.

More from Xinxin Wang

2:45
Challenges faced with the production of universal CAR-T products
Martina Sersch et al. • 14 Apr 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals